Patent ID: 8975296
Filing Date: 2015-03-10
Classification: A61K,A61P,Y10S

Abstract:
1. A pharmaceutical composition comprising from 1% to 95% by weight of an amorphous cathepsin K inhibitor system and from 5% to 99% by weight of excipients comprising a diluent, a glidant, a lubricant, a surfactant and a disintegrant, wherein the amorphous cathepsin K inhibitor system comprises a cathepsin K inhibitor, which is N 1 -(1-cyanocyclopropyl)-4-fluoro-N 2 -{(1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)-1,1′-biphenyl-4-yl]ethyl}-L-leucinamide, and a polymer selected from the group consisting of HPMCAS, copovidone, cellulose acetate phthalate, cellulose acetate succinate, methylcellulose phthalate, ethylhydroxycellulose phthalate, polyvinylacetatephthalate, polyvinylbutyrate acetate, vinyl acetate-maleic anhydride copolymer, styrene-maleic mono-ester copolymer, methyl acrylate-methacrylic acid copolymer, methacrylate-methacrylic and acid-octyl acrylate copolymer.